Pluristem Therapeutics (NASDAQ:PSTI) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01, Fidelity Earnings reports.
NASDAQ:PSTI traded up $0.01 during trading hours on Friday, reaching $1.19. 84,903 shares of the company’s stock were exchanged, compared to its average volume of 228,865. The stock has a market cap of $131.77 million, a P/E ratio of -4.76 and a beta of 0.48. Pluristem Therapeutics has a 1-year low of $1.06 and a 1-year high of $1.65.
A number of brokerages recently weighed in on PSTI. Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 12th. B. Riley began coverage on shares of Pluristem Therapeutics in a research note on Tuesday, July 31st. They set a “buy” rating and a $4.50 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $3.50 price target on shares of Pluristem Therapeutics in a research note on Friday, September 28th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $3.13.
TRADEMARK VIOLATION WARNING: “Pluristem Therapeutics (PSTI) Announces Earnings Results, Beats Expectations By $0.01 EPS” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2018/11/09/pluristem-therapeutics-psti-announces-earnings-results-beats-expectations-by-0-01-eps.html.
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.